课题基金 / 基金详情

Cancer Research Training Program: From Molecular Mechanisms to Therapeutic Strategies

Cancer Research Training Program: From Molecular Mechanisms to Therapeutic Strategies
癌症研究培训计划:从分子机制到治疗策略
批准号:
10685245
负责人:
Andrew Carl Dudley
金额:
$42.77万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1976
资助国家:
美国
项目状态:
未结题
起止时间:
1976-07-01 至 2027-06-30

项目摘要

项目成果

Andrew Carl Dudley的其他基金

相似基金

相关文献

中文摘要
翻译
摘要 弗吉尼亚大学的癌症研究培训计划(CRTP)将教职员工和 对癌症生物学有共同兴趣的学员参加癌症研究的综合计划, 教育和发现。CRTP的总体目标是让下一代癌症患者 研究人员拥有成为未来领导者的工具,以寻求了解肿瘤学过程和 改善患者的预后。我们通过密集的癌症研究培训和再加上 学术和职业发展活动。总而言之,这些为学员提供了(1)基础广泛的 癌症生物学基本原理的知识;(2)定义和解决重要研究的能力 在不断变化的环境中使用最新的方法和技术进行提问 生物医学研究;以及(3)与基础科学家、转化研究人员、临床研究人员合作的技能 试验者、临床医生和癌症患者/幸存者,以促进发现和改善结果。此次续订 应用程序纳入了一个新的领导结构,这是由于安德鲁·达德利博士的加入 多名私家侦探和现任私家侦探艾米·鲍顿博士。我们请求支持8名博士后实习生,他们将 参加纵向培训,包括实验室研究、正规课程工作、计划 活动,接触癌症的临床/翻译方面,专业/职业规划 发展和社区外展机会。42名CRTP教师导师提供了强大和全面的 该计划通过其提供此培训的集成平台。最重要的是,CRTP采取了 NCI指定的UVA癌症中心提供强大的癌症研究社区的优势。这 为学员提供机会将他们在基础癌症研究方面的经验应用于 改进癌症护理中的诊断和治疗。CRTP经历了近几年的成功 44年的历史。随着我们进入下一个资金期,我们挑战自己,以适应不断变化的 通过不断的评估和方案的演变来研究癌症的前景。在这方面,我们 纳入了一系列旨在加强社区建设、提供新的 提供应用学习和专业发展的机会,并促进学员和 癌症患者/幸存者。此续订申请还包括重点关注以下方面的重要新增强功能 严格和可再现性方面的培训、导师培训,并设立一个咨询委员会 多样性和包容性。全系列的CRTP活动,以及一支敬业的教职员工,优秀的干部队伍 实习生和充满活力的癌症研究社区,都有助于培养出优秀的CRTP校友- 在不断发展的癌症研究领域成为终身学习者和未来的领导者。
英文摘要
ABSTRACT The Cancer Research Training Program (CRTP) at the University of Virginia brings together faculty and trainees with a common interest in cancer biology to participate in an integrated program of cancer research, education, and discovery. The overall objective of the CRTP is to empower the next generation of cancer researchers with the tools to become future leaders in the quest to understand oncological processes and improve patient outcomes. We accomplish these goals through intensive cancer research training coupled with academic and professional development activities. Together, these provide the trainees with (1) a broad-based knowledge of fundamental principles in cancer biology; (2) the ability to define and solve vital research questions using the most current approaches and techniques in the constantly changing landscape of biomedical research; and (3) the skills to partner with basic scientists, translational researchers, clinical trialists, clinicians, and cancer patients/survivors to promote discovery and improved outcomes. This renewal application incorporates a new leadership structure prompted by the addition of Dr. Andrew Dudley as part of a multi-PI team with the current PI, Dr. Amy Bouton. We request support for 8 predoctoral trainees who will participate in longitudinal training that includes laboratory research, formal course work, programmatic activities, exposure to clinical/translational aspects of cancer, programming in professional/career development, and community outreach opportunities. The 42 CRTP faculty mentors provide a robust and fully integrated platform through which the program delivers this training. Most importantly, the CRTP takes advantage of the robust cancer research community provided by the NCI-designated UVA Cancer Center. This affords the trainees an opportunity to apply their own experiences in basic cancer research to the need for improved diagnosis and treatments in cancer care. The CRTP has experienced much success over its almost 44-year history. As we move into the next funding period, we challenge ourselves to meet the changing landscape of cancer research through constant assessment and evolution of the program. In this regard, we have incorporated a number of new initiatives designed to reinforce community-building, provide new opportunities for applied learning and professional development, and promote dialogues between trainees and cancer patients/survivors. This renewal application also includes important new enhancements focused on training in rigor and reproducibility, mentor training, and the establishment of an Advisory Committee for Diversity & Inclusion. The full array of CRTP activities, together with a dedicated faculty, talented cadre of trainees, and vibrant cancer research community, all contribute to producing CRTP alumni who are well- positioned to become lifelong learners and future leaders in the continually evolving field of cancer research.
期刊论文(36)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.isci.2020.101855
发表时间: 2020-12-18
期刊: iScience
影响因子: 5.8
作者: [Costa-Pinheiro P, Heher A, Raymond MH, Jividen K, Shaw JJ, Paschal BM, Walker SJ, Fox TE, Kester M]
通讯作者: Kester M
Nucleotide sequence of the btuCED genes involved in vitamin B12 transport in Escherichia coli and homology with components of periplasmic-binding-protein-dependent transport systems.
参与大肠杆菌中维生素 B12 转运的 btuCED 基因的核苷酸序列以及与周质结合蛋白依赖性转运系统成分的同源性。
DOI: 10.1128/jb.167.3.928-934.1986
发表时间: 1986
期刊: Journal of bacteriology
影响因子: 3.2
作者: [Friedrich,MJ, deVeaux,LC, Kadner,RJ]
通讯作者: Kadner,RJ
Generation of IL-2-dependent cytolytic T lymphocytes (CTLs) with altered TCR responses derived from antigen-dependent CTL clones.
产生 IL-2 依赖性溶细胞 T 淋巴细胞 (CTL),其 TCR 反应发生改变,源自抗原依赖性 CTL 克隆。
DOI: --
发表时间: 1999
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Gullo,CA, Esser,MT, Fuller,CL, LamBraciale,V]
通讯作者: LamBraciale,V
DOI: 10.1084/jem.187.7.1057
发表时间: 1998-04-06
期刊: The Journal of experimental medicine
影响因子: --
作者: [Esser MT, Haverstick DM, Fuller CL, Gullo CA, Braciale VL]
通讯作者: Braciale VL
共 26 条
    Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
    Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
    Tumor Endothelial Cell Regulation of Pro-Metastatic Fibrin Matrices
    Mechanisms of tumor escape from anti-angiogenic therapy
    海外基金